Ranitidine Litigation Opens With Settlements, But Still Massive With State And MDL Trials Pending

GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.

• Source: Shutterstock

Settlements by four generic manufacturers in a a single ranitidine product liability case gives some sense of what global resolutions might entail. However, brand companies may opt to go to trial rather than settle, as GlaxoSmithKline plc and Sanofi have indicated.

The first trial in the ranitidine litigation had been scheduled to begin on 22 August in Illinois state court before counsel for the plaintiff told the court on 15

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Ingredients & Safety

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By 

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By 

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

Plenty For Industry To Do As EU Wastewater Directive Faces Legal Challenges

 
• By 

Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By 

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

More from HBW Insight

Estee Lauder Taps Iconic Creative Director For MAC, Indian Personal Care Firm Appoints Chief Commercial Officer For Hair Care; Beauty News

 

MAC Cosmetics Appoints ‘Iconic’ Creative Director Nicola Formichetti as global creative director, while Revlon Consumer Products LLC partners with four-time GRAMMY-nominated artist, Ice Spice, in a “major step” in the revitalization of Revlon’s fragrance business.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.